KRAS and adenomyosis: A recent study [31] has indicated that KRAS mutations are more frequent in cases of adenomyosis with co-occurring endometriosis, leading to a reduced efficacy of progestin therapy by the silencing of PGR, and can be a driver for adenomyosis development as described in further detail in the adenomyosis section below.